Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.

A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...

Monepantel is under clinical development by Neurizon Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

EST Denali falls 9% to $18 afteramyotrophic lateral sclerosis study missDon't Miss Our New Year's Offers:Discover the latest stocks ...

Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...

Amyotrophic lateral sclerosis (ALS) is a serious and usually fatal neurodegenerative disorder in which motor neurons deteriorate and die. | Genetics And Genomics ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...